Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

NCT01025479 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01025479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01025479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
November 30, 2009
Completion date
March 31, 2010
Enrollment
829 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, prostate cancer